Clinical Trials
10 trialsNCT04527991 2026-06-02
TROPiCS-04
Gilead Sciences
Phase 3 Completed
NCT05226117 2026-03-27
Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer
IRCCS San Raffaele
Phase 2 Completed
NCT03869190 2026-01-22
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Hoffmann-La Roche
Phase 1/2 Completed
NCT05520723 2025-12-04
PRIMED
MedSIR
Phase 2 Completed
NCT04319198 2025-09-30
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Gilead Sciences
Phase 4 Completed
NCT04381832 2025-07-22
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT03901339 2024-10-21
TROPiCS-02
Gilead Sciences
Phase 3 Completed
NCT03995706 2024-09-04
Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0
The University of Texas Health Science Center at San Antonio
Phase EARLY_PHASE1 Completed
NCT02574455 2022-06-15
ASCENT
Gilead Sciences
Phase 3 Completed
NCT01631552 2021-08-12
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Phase 1/2 Completed